Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age

Inclusion Criteria: * Children or adolescents 6 to 18 years of age with DMD-associated cardiomyopathy, followed either as in- or outpatients, will be eligible for inclusion. * Currently on heart failure medication (any drug or any combination). * Patients should potentially benefit from adding a SGLT2i (as judged by the treating physician and the PI or Co-PI). * Patients need to be on stable medical treatment, defined as no new heart failure drug started over the preceding 2 weeks and no major drug dose modification (apart minor adaptations, like weight adaptations, rounding or formulation changes) during the 2 weeks prior to enrolment. * Adolescents, respectively parents or caregivers of children, capable of giving informed consent. * Ability to tolerate a cardiac MRI investigation without the need of general anaesthesia. Exclusion Criteria: * Inability to understand and go through the informed consent procedure. * Inability to receive medications per os or through a nasogastric tube. * Type 1 or Type 2 Diabetes mellitus or any underlying metabolic disease associated with hypoglycaemias. * Body weight \<15kg. * Current smokers (defined as \>1 cigarette/week). * Use of any other nicotine-delivering product (e.g. nicotine patches). * Any known illicit drug abuse. * Active chronic HBV, HCV or HIV. * Any major surgery within 4 weeks of first dose administration. * Blood transfusion recipient within 4 weeks of dose administration. * eGFR \<45mL/min/1.73m2 (simplified Schwartz …